Syros Pharmaceuticals, Inc.
SYRSDelisted Mar 10, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001556263
Syros Pharmaceuticals, Inc. was delisted on Mar 10, 2025; its insiders filed their last Form 4 on Dec 4, 2024; 44 institutions reported holding it in 13F filings for Q4 2024, worth $1.20M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding Syros Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 100 | 1 | 100 | +1 |
| Shares | 50.9M | 64.0K | 50.1M | −690.6K (−1.4%) |
| Value | $276.0M | $349.0K | $223.1M | −$52.5M (−19.1%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Syros Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Franklin Resources Inc | 64,000 | $286.0K | 0.00% |
| Price T Rowe Associates Inc | 49,084 | $219.0K | 0.00% |
| LGT Capital Partners Ltd. | 43,388 | $194.0K | 0.01% |
| Walleye Capital LLC | 33,227 | $149.0K | 0.00% |
| Summit Global Investments | 31,800 | $142.0K | 0.01% |
| SG Americas Securities, LLC | 31,096 | $139.0K | 0.00% |
| ExodusPoint Capital Management, LP | 30,675 | $137.0K | 0.00% |
| Ieq Capital, LLC | 27,800 | $124.0K | 0.00% |
| MetLife Investment Management | 21,697 | $97.0K | 0.00% |
| Virtu Financial LLC | 20,940 | $94.0K | 0.01% |
| Metropolitan Life Insurance Co | 16,415 | $73.4K | 0.00% |
| Occudo Quantitative Strategies LP | 16,323 | $73.0K | 0.01% |
| Lindbrook Capital, LLC | 514 | $2.00K | 0.00% |
| Quadrant Capital Group LLC | 114 | $1.00K | 0.00% |
| Bogart Wealth, LLC | 15 | $0 | 0.00% |
| IFP Advisors, Inc | 50 | – | – |
Sold out (15)
Institutions that held Syros Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| EcoR1 Capital, LLC | 1,000,000 | $5.45M |
| Acadian Asset Management LLC | 354,453 | $1.93M |
| Engineers Gate Manager LP | 82,200 | $448.0K |
| Qube Research & Technologies Ltd | 78,774 | $429.0K |
| Baker Bros. Advisors LP | 65,497 | $357.0K |
| Hancock Whitney Corp | 27,860 | $152.0K |
| XTX Topco Ltd | 26,018 | $142.0K |
| Group One Trading, L.P. | 23,348 | $127.0K |
| Raymond James & Associates | 15,500 | $84.0K |
| Prelude Capital Management, LLC | 14,200 | $77.0K |
| Caas Capital Management LP | 13,905 | $76.0K |
| Fox Run Management, L.L.C. | 12,826 | $70.0K |
| Quantbot Technologies LP | 1,300 | $7.00K |
| Capital Advisory Group Advisory Services, LLC | 700 | $4.00K |
| Panagora Asset Management Inc | 428 | $2.00K |
Not filed for Q3 2021 yet (1)
Institutions that held Syros Pharmaceuticals, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| QS Investors, LLC | 64,000 | $349.0K |